A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain
Latest Information Update: 29 Nov 2024
At a glance
- Drugs LAT 8881 (Primary)
- Indications Pain; Radiculopathy
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Lateral Pharma Pty Ltd
Most Recent Events
- 27 Jul 2023 Status changed from recruiting to completed.
- 01 Feb 2023 Planned End Date changed from 1 Nov 2022 to 1 Jun 2023.
- 01 Feb 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Mar 2023.